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The biodistribution of 227Th-EDTMP and retention of its daughter nuclide 223Ra were 
examined. 227Th-EDTMP was found to show high uptake and long-term retention in bone. The 
clearance of 227Th-EDTMP from blood and soft tissues was rapid and the femur-to-tissue uptake 
ratios reached more than 100 within 30 min for all tissues except the kidney. Seven and 14 days 
after injection of 227Th-EDTMP, the retention index of 223Ra in bone showed high values, and 
the differences between these time points were not significant. Therefore, 227Th-EDTMP is a 
potential radiotherapeutic agent for bone metastasis. 
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1. Introduction 
 
Most patients with advanced breast, prostate, or lung carcinoma develop bone metastases [1]. 
Bone metastasis causes severe pain, so there have been many attempts to develop curative 
treatment regimens. Various treatment methods, including analgesic therapy, external radiation 
therapy, hormonal therapy, chemotherapy, and surgical invention, have been used to improve 
responses, but many of these treatments are limited in their efficacy or duration and have 
significant side effects [2]. β-emitting radiopharmaceuticals for bone targeting, such as 32P 
orthophosphate and 89Sr chloride, have been used clinically for treatment of bone pain [2,3].  
Although these β-emitters relieve bone pain associated with metastatic lesions in the skeleton, 
bone marrow toxicity limits use of high dose radiations to prevent tumor progression due to the 
long radiation range of β-particles. To overcome this drawback, clinical use of several 
low-energy β-emitters, including 153Sm and 186Re [4-6], and the conversion electron emitter 
117mSn [7], have been examined. Among these radionuclides, 153Sm complexed with 
ethylenediamine-tetramethylenephosphonic acid (EDTMP) has been approved for use in 
palliation of bone pain by the U.S. FDA. 
Due to the high LET and short range of α-particles in tissue in comparison with β-particles, 
α-emitting nuclides are promising for the treatment of bone metastases. Reduction of bone 
marrow exposure can be achieved due to the short range of α-particles. A comparative study 
using bisphosphonates labeled with α-emitting 211At and β-emitting 131I indicated that the bone 
surface-to-bone marrow ratio was threefold higher with 211At than with 131I [8]. In addition to 
their physical properties (short range with high LET), many suitable α-emitting nuclides 
undergo successive α- and β-cascade disintegrations. These multiple α-emissions at tumor sites 
are more effective than single α-emission irradiation. In recent studies with α-emitting 233Ra and 
β-emitting 89Sr, dosimetry also indicated intense and highly localized radiation dose from 223Ra 
and its progeny to the bone surface with substantially less irradiation of healthy bone marrow as 
compared with β-emitting 89Sr [9]. Moreover, only very small amounts of 211Bi, the progeny 
nuclide of 223Ra, redistributed from the sites of 223Ra decay in the bone [9]. These results 
suggested the usefulness of cascade α-emission in the treatment of bone metastases. 
Thorium-227 (t1/2 = 18.72 d) is a promising α-emitting radiotherapeutic nuclide for treatment 
of bone metastases. It has a more suitable half-life for treatment of bone metastases as compared 
with other thorium isotopes, such as 232Th (t1/2 = 1.405 × 1010 y) and 228Th (t1/2 = 1.9116 y). 227Th 
belongs to the actinium series (Fig. 1), and emits α-particles with an average energy of 5.9 MeV 
decaying to 223Ra. The daughter nuclide 223Ra also decays to stable 207Pb with emission of about 
28 MeV. As the half-lives of 227Th and 223Ra (t1/2 = 11.435 d) are similar, it will be possible to 
avoid the high-dose α-particles of 223Ra and its progeny nuclides during the initial phase of renal 
clearance after administration of radioactive pure 227Th. In addition, the radioactive growth of 
223Ra will prolong the effective irradiation duration. The relatively low energy γ-rays of 227Th 
will be useful for imaging, and its daughter nuclide 223Ra also emits γ-rays that are available for 
monitoring. The parent 227Ac (t1/2 = 21.773 y) has a long half-life so that 227Th is available from 
the 227Ac/227Th generator system. 
Although Th is a well-known bone-seeking element, it also accumulates in other tissues [10, 
11]. However, Larsen et al. reported selective accumulation of thorium labeled bis- and 
polyphosphonate in bone [12]. 227Th was complexed with the ligands 
diethylenetriamine-N,N’,N’’-pentamethylene-phosphonic acid (DTPMP) and  
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylenephosphonic acid (DOTMP), and it was 
shown to be retained on bone with high uptake ratios of bone-to-soft tissue compared to the 
acetate salt of 227Th [12]. Although 227Th-polyphosphonates were accumulated selectively in 
bone, retention of the daughter nuclide 223Ra from 227Th was not clear. 
In this study, the biodistribution of 227Th-EDTMP over a period of 14 days in mice was 
compared with that of 227Th-citrate, and the retention of the daughter nuclide 223Ra in bone was 
also examined. The potential of 227Th-EDTMP as a therapeutic agent for bone metastasis is 
discussed. 
 
2. Materials and methods 
 
2.1. 227Th preparation 
 
227Th was separated from the parent nuclide 227Ac by ion exchange chromatography using 
strong anion exchange material as described by Müller [13]. 227Ac solution was obtained from 
the Oarai Branch, Institute for Materials Research, Tohoku University, and sufficiently reached 
equilibrium state with 227Th and its daughter nuclides. The 227Ac solution prepared in 7 M HNO3 
was loaded onto a 5 × 42 mm column containing Muromac AG1×8 anion exchange resin 
(Muromachi Technos Co., Ltd., Tokyo, Japan) pre-equilibrated with 7 M HNO3. The column 
was washed with 15 mL of 7 M HNO3 to remove the parent 227Ac and daughter nuclides of 
227Th. After purification, 227Th was eluted with 20 mL of 1 M HCl. The eluted 227Th solution 
was evaporated to dryness, then re-dissolved in 7 M HNO3 and prepared as a stock solution. 
 
2.2. Preparation of 227Th-EDTMP and 227Th-citrate 
 
EDTMP was purchased from Dojindo Laboratories (Kumamoto, Japan) and used without 
further purification. Before preparation to 227Th-EDTMP, 227Th solution was purified to remove 
223Ra and its daughter nuclides (223Ra-free solution). 227Th solution was finally prepared in 2 mL 
of 0.2 M HCl. The 227Th solution was added to 0.21 mL of 0.2 M EDTMP in 0.2 M NaOH and 
heated for 5 min in boiling water after adjusting the pH to 6.6 with 1.45 mL of 1 M NaOH. 
Finally, pure water was added to adjust the solution to physiologically isosmotic concentration 
and 4.2 mL of the final 227Th-EDTMP (10 mM EDTMP) solution was prepared. Radiochemical 
purity of 227Th-EDTMP was determined using miniature paper chromatography [14] with 25% 
acetone solvent prior to animal experiments. 
227Th-citrate was prepared by adding 1.8 mL of 3.02% (v/v) physiological sodium citrate 




Male ICR mice (n = 51, 7 weeks old, 35.3 ± 1.3 g) were purchased from Japan SLC, Inc. 
(Hamamatsu, Japan) and housed at the Kanazawa University Animal Experiment Facility. The 
mice were given certified diet and tap water ad libitum. Animal studies were conducted 
according to the Guidelines for the Care and Use of Laboratory Animals of Takara-machi 
Campus of Kanazawa University, and the experimental procedures were approved by the 
Committee on Animal Experimentation of Kanazawa University, Takara-machi Campus. 
 
2.4. Biodistribution of 227Th-EDTMP and 227Th-citrate 
 
Thirty-six mice were administered 100 µL of physiologically isosmotic 227Th-EDTMP 
containing 60.3 kBq of 227Th via the tail vain. Biodistribution was determined in three mice at 
each of 15 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr, 1 day, 3 days, 5 days, 7 days, 10 days, and 14 
days post-administration. After sacrifice, the following 7 samples were collected from each 
mouse and weighed: femur, parietal bone, liver, kidney, spleen, lung, muscle, and whole blood.  
Fifteen mice were administered 100 µL of physiological 227Th-citrate (3.02% (v/v) sodium 
citrate) containing 37.2 kBq of 227Th via the tail vain. Its biodistribution was determined in three 
mice at each of 15 min, 1 hr, 6 hr, 1 day, and 7 days post-administration. After sacrifice, the 
following samples were collected and weighed: femur, parietal bone, liver, kidney, spleen, lung, 
muscle, stomach, large intestine, small intestine, and whole blood. 
The 227Th radioactivity in each sample tissue was determined by γ-ray spectrometry using a 
high purity Ge detector (EG&G ORTEC, Oak Ridge, TN, USA) coupled with a multi-channel 
analyzer, MCA-7800 (Seiko EG&G Co., Ltd., Tokyo, Japan). The most abundant 235.97 keV 
γ-ray was used for determination (Table 1). The results are expressed as percent injected dose 
per gram (%ID/g) of tissue. 
 
2.5. Retention of 223Ra generated from 227Th in bone 
 
To evaluate retention of 223Ra generated from 227Th in bone, γ-ray spectrometry was 
performed on femur samples obtained 7 and 14 days post-administration. The γ-ray 
spectrometry was performed on femur samples immediately after sacrifice to prevent 
radioactive growth of 223Ra. The data thus obtained were compared with those of a standard 
227Th source prepared from 223Ra-free solution. Analyses were performed using 235.97 keV 
γ-ray of 227Th and 154.21 keV γ-ray of 223Ra (Table 1). The standard source was measured in the 
same geometry as the femur sample to be consistent with γ-ray efficiency on Ge detectors. The 
retention based on relative counting rate (CR) of 227Th and 223Ra in samples vs. the standard was 
determined as (CR of 223Ra in sample/CR of 227Th in sample)/ (CR of 223Ra in standard/CR of 




3.1. Complexation yield 
 
The yield of the carrier free 227Th-EDTMP complex was 99% of the total activity in the 
original solution. 
 
3.2. Biodistribution of 227Th-EDTMP and 227Th-citrate 
 The biodistribution of 227Th-EDTMP is summarized in Table 2. The results showed that the 
uptakes of 227Th-EDTMP by bone were higher than those by other soft tissues. Femur and 
parietal bone uptake rates rapidly reached the maximum level at 30 min and remained at a 
constant level throughout the 14-day experimental period. On the other hand, soft tissues except 
the kidney showed uptakes of less than 1%ID/g at 15 min post-injection. The uptakes by blood, 
kidney, lung, and muscle decreased with time after administration. Those by the liver and spleen 
decreased until 1day post-injection, and then increased until day 14. 
The biodistribution of 227Th-citrate is shown in Table 3. The results also indicated high uptake 
rates in the femur and parietal bone during the 14-day experimental period. The maximum 
uptake level was 28.45%ID/g for the femur at 1 day post-injection. This value was threefold 
higher than that of 227Th-EDTMP. Although uptake rates of blood decreased rapidly with time 
after injection, those of the muscle and lung showed slight decreases and those of other soft 
tissues changed little during the 14-day experimental period. 
Figure 2 compares the femur-to-soft tissue uptake ratios of 227Th-EDTMP to 227Th-citrate. 
The ratios of 227Th-EDTMP were higher than those of 227Th-citrate between 15 min and 14 days 
after injection. The ratios of 227Th-EDTMP reached more than 100 only 1 hour after injection in 
all tissues except the kidney. 
 
3.3. Retention of 223Ra generated from 227Th in bone 
 
Table 4 shows the retention index of 223Ra relative to 227Th in the bone at 7 and 14 days 
compared with a standard radioactive source. The index values were high and the differences 
between these two time points were not significant. As γ-ray spectrometry was performed within 
30 min after sacrifice, radioactive growth of the daughter nuclide 223Ra were ignored due to its 
relatively long half-life. Fresh 227Th-EDTMP was injected within 2 hours after preparation, and 
so it was estimated that mice received less than 0.5% 223Ra radioactivity as compared to 227Th. 




The bone uptake of 227Th-EDTMP in mice was found to be high and selective as compared 
with other tissues. Moreover, 227Th-EDTMP was retained in bone throughout the 14-day 
experimental period. The clearance of 227Th-EDTMP from soft tissues was rapid compared with 
its physical half-life. Although Th is a well-known bone-seeking element, it also accumulates in 
other tissues. There have been several reports regarding the biological behavior of Th isotopes 
[10, 11], which indicated some retention of Th in soft tissues. Our results using 227Th-citrate also 
indicated that the %ID/g of 227Th retained in the kidney, liver, spleen, and other tissues was low. 
The difference in biodistribution between 227Th-EDTMP and 227Th-citrate was due to differences 
in the bioavailability of these chelates. 227Th-citrate would initially bind to bone according to the 
chemical absorption of Th(IV) to hydroxyapatite, while 227Th-EDTMP would bind to bone by 
bridging of 227Th to hydroxyapatite by the multidentate phosphonate chelate system [15]. 
Therefore, our comparative study of 227Th-EDTMP and 227Th-citrate demonstrated the efficacy 
of 227Th-EDTMP for bone-affinity radiopharmaceuticals. EDTMP chelate has at least eight 
protonation sites [16] and it binds readily with bi- and trivalent metal radioisotopes, such as 
154Sm, 186Re, 177Lu, 105Rh, 212Pb, and 212Bi, which were thought to have potential for use in 
treatment of bone metastases [17-21]. Although there were several differences in the uptake 
rates among these EDTMP complexes, the tendencies to accumulate in bone and to be 
eliminated rapidly from other tissues were seen in all cases. The uptake rate of 227Th-EDTMP in 
bone was lower than those of the other 227Th-labeled polyaminophosphonates, 227Th-DTPMP 
and 227Th-DOTMP [12]. This was most likely due to differences in the body weight of mice 
between the two studies. However the femur-to-other tissue uptake ratios of 227Th-EDTMP were 
high in comparison with those of 227Th-DTPMP and 227Th-DOTMP [12], and reached more than 
100 at only 1 hour after injection in all tissues except the kidney. These results showed that the 
clearance of 227Th-EDTMP from soft tissues through blood flow was superior to those of 
227Th-DTPMP and 227Th-DOTMP. Thus, 227Th-EDTMP is promising as a radiopharmaceutical 
for bone metastases. 
In radionuclide therapy, many available α-emitting nuclides undergo successive α- and 
β-cascade disintegrations [22]. Whether these successive radiations could deliver high-dose 
irradiation to tumor foci is dependent on retention of daughter nuclides produced in vivo. Here, 
we examined the retention of the daughter nuclide 223Ra produced from 227Th in the femur. The 
retention index of 223Ra in the femur was determined using γ-ray spectrometry as the relative 
radiation count rate of 223Ra and 227Th vs. standard. The retention index in the femur indicated a 
high degree of retention of 223Ra on days 7 and 14 after injection of 227Th-EDTMP. Based on the 
physical and chemical conditions after radioactive disintegration, 223Ra could not remain in 
chelate form with EDTMP due to the α-recoil energy and/or low chemical stability of Ra with 
EDTMP. However, Ra is a well-known bone-seeking element [9, 23-25]. Therefore, even if 
223Ra is eliminated from the bone after decay of 227Th, 223Ra is redistributed on bone and 
provides an effective dose to the bone surface. Our results were consistent with those for 228Th 
and its daughter 224Ra in beagles reported by Stover et al. [26] and Lloyd et al. [27]. Henriksen 
et al. reported high retention of the progeny 211Bi in bone from 223Ra [9]. As there are no 
physical or biological differences in the bio-behavior between 223Ra injected directly and that 
generated in vivo after 227Th injection, the progeny generated from 223Ra are expected to also be 
retained on the bone. There have been several other experiments regarding redistribution of 
daughter nuclides for treatment of skeletal metastasis. Using 212Pb-DOTMP, it was found that 
newly generated 212Bi was retained in bone at a rate of 70-85% [28]. Our previous results 
regarding 225Ra bio-behavior in mice demonstrated that large fractions of 221Fr and 213Bi were 
eliminated from 225Ra-deposited bone despite the high degree of retention of 225Ac [29]. The 
present and previous studies suggest that most radionuclides are distributed first according to 
their chemical characteristics. In the case of mother nuclides, such as 227Th and 225Ra, which are 
selectively accumulated in bone, daughter nuclides, such as 223Ra and 225Ac, are also retained 
selectively on bone according to their bone affinity. Second, even if daughter nuclides have no 
bone affinity, the relatively short half-lives of daughter nuclides, such as 219Rn and 215Po, 
compared to 220Rn and 221Fr result in their retention at their site of generation as they show faster 
disintegration than chemical migration. 
In a closed system, the decay and growth of radioactivity of 227Th and 223Ra are expected to 
be as illustrated in Fig. 5. In the case of 223Ra administration, 223Ra decays according to its 
half-life with 4 α-emissions due to radioactive equilibrium with its progeny. The highest 
radiation dose is reached at 4 hours post-injection. On the other hand, in the case of 227Th 
administration, 227Th also decays according to its half-life, but α-emitted radioactivity increases 
with time and reaches the maximum level after 17 days, then begins to decrease. Therefore, 
227Th administration yields prolongation of effective α-radiation dose. In general, accumulation 
of 223Ra in bone and its clearance from other tissues are expected to be rapid after 223Ra 
administration [9], and 223Ra easily reaches secular equilibrium with daughter nuclides, such as 
219Rn and 215Po, within 30 seconds and also with 211Pb and 211Bi within 4 hours. Therefore, the 
kidney, spleen, and other soft tissues might be exposed to large radiation doses from cascade 
α-emissions in the initial phase. However, in the case of 227Th-EDTMP administration, 227Th 
contributes a slowly growing radiation dose to bone and a lesser dose of irradiation to non-target 
tissue. The antitumor effects of 223Ra were examined; this radionuclide was demonstrated to 
show significantly increased symptom-free survival, and no signs of bone marrow toxicity or 
body weight loss [25]. There were no significant changes in biodistribution pattern between 
227Th-EDTMP and 223Ra. The 227Th chelate would be expected to have effective antitumor 
activity. We are currently planning to evaluate the antitumor effects of 227Th.  
In conclusion, 227Th-EDTMP showed selective accumulation and long-term retention in bone, 
with rapid clearance from soft tissues. The retention of the daughter nuclide 223Ra was high 
during the 14-day experimental period after administration of 227Th, and so it would be expected 
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Figure captions 
Fig. 1. Decay chain of 227Ac to stable 207Pb. 
 
Fig. 2. The bone-to-tissue uptake ratios of 227Th-EDTMP and 227Th-citrate. 227Th-EDTMP and 
227Th-citrate are shown as (○) and (■), respectively. All data are shown with errors based on S.D. 
for 3 animal experiments. 
 
Fig. 3. The radioactive decay and growth patterns of 227Th and 223Ra in a closed system. Gross 












































































































































   









   












   









   











   













Decay properties of 227Th and 223Ra
Nuclide half-life γ-rays
keV (%)










Data were taken from Table of Isotopes, 8th ed. John Wiley and Sons, Inc., (1996);
a: More than 2% abundant γ-rays are listed for each radionuclide;
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Retention index of 223Ra on the femur
Retenion Index
day 7 0.85 ± 0.04
day 14 0.89 ± 0.02
